Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Longer term treatment reduces risk of repeat heart attacks

Study shows longer term treatment reduces risk of repeat heart attacks


A new international study of 21,000 people who had suffered heart attacks has shown that their risk of repeat heart attacks is significantly reduced if they are treated with a medicine called BRILINTA® (ticagrelor) in addition to aspirin and continued for up to three years, compared to the current standard of care, which is treatment with aspirin alone.

BRILINTA is a heart medication that helps stop the clumping of platelets. This reduces the chance of a blood clot forming that can reduce blood flow.

More than 15,000 New Zealanders currently suffer a heart attack each year. Recent research has shown that one in five heart attack patients will have a further heart attack, stroke or cardiovascular (CV) event in the three years following a heart attack.

A new major study, PEGASUS-TIMI 54 (PEGASUS), presented at the American College of Cardiology 64th Annual Scientific Session, and published in the New England Journal of Medicine, has shown that people who had experienced a heart attack at least one year prior to study enrolment had a reduced combined risk of cardiovascular death, repeat heart attack or stroke after being treated with BRILINTA tablets plus low dose aspirin for a longer period, compared to those treated with aspirin alone.

In this trial, at 3 years both doses of BRILINTA were shown to significantly reduce the combination of CV death, heart attack or stroke compared to treatment with aspirin alone. In addition, the reduction in CV events with both doses of BRILINTA appeared consistent across major subgroups including, but not limited to, age, sex and type of heart attack.

Dr Gerard Devlin, cardiologist at Waikato Hospital, said the study had identified a group of patients at high risk who stood to benefit from a new approach to extended treatment.
Virginia Sutherland, General Manager of AstraZeneca in New Zealand, said: “As a company we are committed to cardiovascular research and are proud to have delivered the PEGASUS study which is both one of AstraZeneca’s largest clinical trial and the first prospective trial to evaluate longer term dual antiplatelet therapy in higher risk patients with a history of a heart attack.

Major bleeding is a recognised side effect of this class of medicine. Major bleeding was higher with BRILINTA than with aspirin alone, but importantly rates of fatal bleeding were low and were similar between the patients treated with BRILINTA and those treated with aspirin alone.

Long term treatment presented challenges in managing side effects, Dr Devlin said, making it important to assess patients who were best suited for the treatment. “But the good thing in this study is that while there was an increased risk of bleeding in people treated with BRILINTA this did not result in death or intracranial haemorrhage [bleeding within the skull]”.

He also welcomed the study’s finding that the 60mg dose of BRILINTA with aspirin had similar efficacy to the 90mg dose. “That means patients may require less medication to reap its benefits, and may experience fewer side effects as a result of the lower dose.”

“The key thing for people to remember who have had a heart attack is that they need to look after themselves. Don’t smoke. People also often don’t understand the reasons for the medications they are on and why these are often life-long. I would urge patients to discuss these things with their health care professional and not to stop taking any medication without talking to them. These are lifesaving medications. “

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 


Bell Gully: Uncertainty Ahead With New Unconscionable Conduct Legislation

new prohibition against ‘unconscionable conduct’ in trade is one of a number of changes to the Fair Trading Act 1986 that come into force from 16 August 2022. The new prohibition may have wide-ranging implications for many businesses... More>>


Statistics: Food Prices Increase 7.4 Percent Annually
Food prices were 7.4 percent higher in July 2022 compared with July 2021, Stats NZ said today... More>>



REINZ: Market Activity And Prices Continue To Ease, First Home Buyers Start To Return To The Market

New Zealand’s winter property market continues its recent trend, slowing from the pace of sales and price rises of last year — properties stay on the market longer and median prices dip... More>>



Kiwi Group Holdings: Fisher Funds Acquires Kiwi Wealth Business

Kiwi Group Holdings Limited (KGHL) today announced the sale of Kiwi Wealth to Fisher Funds for NZ$310 million... More>>



Retail NZ: Welcomes Return Of Cruise Ships

“Cruise visitors were big spenders in retail prior to COVID-19, and retailers in Auckland will be celebrating the arrival of P&O’s Pacific Explorer this morning... More>>



ASB: Full Year Results: Building Resilience Today And For Our Future

In its 175th year, ASB has reported a cash net profit after tax of $1,418 million for the 12 months to 30 June 2022, an increase of $122 million or 9% on the prior year... More>>